Rankings / Metabolic Health

Enicepatide (CT388)

Metabolic Health · GLP-1/GIP dual agonist

Tier B-

Reviewed by Read Off Label · Last reviewed · How we grade

incretinglp1-agonistgip-agonistinjectable-peptideinvestigationalweight-loss
5.9 / 10
Tier B-
Ev 6 Bn 8 Sf 5

Bottom line

Read Off Label grades Enicepatide (CT388) as B- (5.9/10) based on moderate evidence, high benefit magnitude, and a med-risk safety profile.

Roche/Genentech's lead injectable incretin (from the Carmot acquisition) — a dual GLP-1/GIP agonist in the tirzepatide mold.

Typical use: Subcutaneous injection, weekly (Phase 2 dosing) — Investigational.

What this is

Roche/Genentech's lead injectable incretin (from the Carmot acquisition) — a dual GLP-1/GIP agonist in the tirzepatide mold. Phase 2 CT388-103 (48 wk) reported clinically meaningful weight loss, and Roche is advancing it to Phase 3 alongside petrelintide plus a Phase 2 multi-arm combination trial mid-2026; detailed figures were shared at ADA 2026 and a Roche investor event on 8 Jun 2026. A second Phase 2 (CT388-104) is running in obesity with type 2 diabetes. Industry-sponsored; peer-reviewed publication pending.

Mechanism

Dual GLP-1 and GIP receptor agonist (same class as tirzepatide) — pairs incretin appetite suppression with insulin sensitization for weight loss; injectable

Dose & route

Subcutaneous injection, weekly (Phase 2 dosing)

Citations

Links go to the source. If a link is dead or you want something re-checked, let me know.

Common questions

Does Enicepatide (CT388) work?
Read Off Label rates the evidence for Enicepatide (CT388) as Moderate and the benefit magnitude as high, producing an overall grade of B- (5.9/10). Roche/Genentech's lead injectable incretin (from the Carmot acquisition) — a dual GLP-1/GIP agonist in the tirzepatide mold.
Is Enicepatide (CT388) safe?
Enicepatide (CT388) has a med risk profile in published human data. Legal status: Investigational (Phase 3 initiated 2026). This is not medical advice — see the disclaimer.
What is the typical dose for Enicepatide (CT388)?
Subcutaneous injection, weekly (Phase 2 dosing)
How does Enicepatide (CT388) work?
Dual GLP-1 and GIP receptor agonist (same class as tirzepatide) — pairs incretin appetite suppression with insulin sensitization for weight loss; injectable

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.